Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (3 quarters reported)
$309M in Q4 2025 → $587M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Biontech Se | 12.0% | Added 147% | 754,550 | $70.2M |
| Roivant Sciences Ltd | 11.7% | Added 121% | 1,932,904 | $68.4M |
| Royalty Pharma PLC | 11.0% | Added 122% | 1,155,809 | $64.8M |
| Ionis Pharmaceuticals Inc | 10.8% | Added 106% | 798,709 | $63.3M |
| Insmed Inc | 10.2% | Added 207% | 559,824 | $59.7M |
| Regeneron Pharmaceuticals | 9.8% | Added 107% | 92,640 | $57.8M |
| Legend Biotech Corp | 5.9% | Trimmed 9.4% | 1,191,522 | $34.4M |
| Alnylam Pharmaceuticals Inc | 5.8% | New | 113,085 | $34M |
| Natera Inc | 5.5% | Trimmed 17% | 118,975 | $32.3M |
| Structure Therapeutics Inc | 4.1% | Added 253% | 446,059 | $23.9M |
| Mineralys Therapeutics Inc | 4.0% | Added 92% | 858,753 | $23.2M |
| Vera Therapeutics Inc | 3.6% | New | 498,832 | $21.4M |
| Generate Biomedicines Inc | 2.4% | Added 39% | 824,679 | $13.9M |
| Procept Biorobotics Corp | 1.8% | Added 78% | 464,920 | $10.5M |
| Avalo Therapeutics Inc | 1.5% | New | 468,666 | $8.66M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 2 quarters.
quarter ended June 30, 2026 · filed August 13, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Pfizer Inc | Exited | −1,593,942 | −$44.8M | — |
| Biontech Se | Added | +449,495 | +$41.8M | 12.0% |
| Insmed Inc | Added | +377,262 | +$40.2M | 10.2% |
| Roivant Sciences Ltd | Added | +1,059,506 | +$37.5M | 11.7% |
| Royalty Pharma PLC | Added | +635,800 | +$35.6M | 11.0% |
| Alnylam Pharmaceuticals Inc | New | +113,085 | +$34M | 5.8% |
| Ionis Pharmaceuticals Inc | Added | +411,806 | +$32.7M | 10.8% |
| Regeneron Pharmaceuticals | Added | +47,840 | +$29.8M | 9.8% |
| Argenx Se | Exited | −35,045 | −$25.6M | — |
| EL Eli Lilly & Co | Exited | −27,279 | −$25.1M | — |
Showing the 10 largest of 20 changes.
quarter ended March 31, 2026 · filed May 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Insmed Inc | New | +182,562 | +$29.9M | 8.2% |
| EL Eli Lilly & Co | Added | +18,972 | +$17.4M | 6.9% |
| Royalty Pharma PLC | Trimmed | −320,641 | −$15.4M | 6.8% |
| Natera Inc | Added | +65,316 | +$13.1M | 7.9% |
| Pfizer Inc | Trimmed | −448,300 | −$12.6M | 12.3% |
| Ionis Pharmaceuticals Inc | Added | +148,426 | +$11.1M | 8.0% |
| Generate Biomedicines Inc | New | +591,800 | +$7.4M | 2.0% |
| Cg Oncology Inc | Exited | −162,005 | −$6.73M | — |
| Procept Biorobotics Corp | New | +261,200 | +$6.53M | 1.8% |
| Mineralys Therapeutics Inc | Added | +236,505 | +$6.41M | 3.3% |
Showing the 10 largest of 18 changes.
Loading...
